| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/13/2022 | 48.15% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 462.96% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 551.85% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 374.07% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 640.74% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 492.59% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 551.85% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 314.81% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 225.93% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 225.93% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 06/20/2018 | 611.11% | B of A Securities | → $24 | Initiates Coverage On | → Buy |
| 11/22/2017 | 492.59% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 11/15/2017 | — | Piper Sandler | Upgrades | Neutral → Overweight |
Sangamo Therapeutics Questions & Answers
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Wedbush on June 13, 2022. The analyst firm set a price target for $5.00 expecting SGMO to rise to within 12 months (a possible 48.15% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Wedbush, and Sangamo Therapeutics their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on June 13, 2022 so you should expect the next rating to be made available sometime around June 13, 2023.
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a with a price target of $0.00 to $5.00. The current price Sangamo Therapeutics (SGMO) is trading at is $3.38, which is within the analyst's predicted range.